← Back to Search

Behavioural Intervention

Aging Assessment Tool for Cancer Patients

N/A
Recruiting
Led By Russell E Glasgow
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > /= 65
Age greater than or equal to 65
Must not have
Age less than 65
Primary language other than English or Spanish
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to develop and test a new system called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP) that will assess geriatric issues, health behaviors, mental health, and social

Who is the study for?
This trial is for cancer patients aged 65 or older who speak English or Spanish and are attending their initial oncology visit. They must be willing to participate in all study activities. It's open to those with various cancers, including leukemia, multiple myeloma, kidney tumors, breast cancer, Hodgkin's lymphoma, prostate cancer, and bladder cancer.
What is being tested?
The trial tests an assessment tool called IA3-CP designed to integrate geriatric issues, health behaviors, mental health assessments along with social determinants of health (SDoH). Patients will either receive the IA3-CP with SDoH considerations or without them to see how well these tools can be implemented and improve care.
What are the potential side effects?
Since this trial involves an assessment tool rather than a medication or medical procedure, traditional physical side effects are not expected. However participants may experience discomfort discussing personal matters related to their health behaviors or mental health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 65 years old or older.
Select...
I am 65 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 65 years old.
Select...
My primary language is neither English nor Spanish.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of referrals made and completed for geriatric, health behavior and SDoH issues
Patient reported receipt of quality illness care
Secondary study objectives
Discussion of IA3-CP related issues in oncologist-patient encounter
Oncologist utility
Proportion of patients that use IA3-CP screening tool

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: IA3-CP with SDoHExperimental Treatment1 Intervention
Assess IA3-CP with SDoH and provide feedback (provider \& patient)
Group II: IA3-CP onlyExperimental Treatment1 Intervention
Assess IA3-CP only without added SDoH and provide feedback (provider \& patient)
Group III: Control - usual careActive Control1 Intervention
Usual care: Assess IA3-CP without providing the feedback report

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,806 Previous Clinical Trials
2,822,842 Total Patients Enrolled
18 Trials studying Leukemia
572 Patients Enrolled for Leukemia
National Cancer Institute (NCI)NIH
13,927 Previous Clinical Trials
41,017,970 Total Patients Enrolled
1,534 Trials studying Leukemia
385,488 Patients Enrolled for Leukemia
Russell E GlasgowPrincipal InvestigatorUniversity of Colorado, Denver
~20 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top